Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218
Treatment and outcome of 2904 CML patients from the EUTOS population-based registryVerena Hoffmann, Rüdiger Hehlmann, Michele Baccarani et al.|Leukemia|2016Cited by 104
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityJoaquín Martínez‐López, Jesús F. San Miguel, María‐Victoria Mateos et al.|Blood Cancer Journal|2020Cited by 78
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2023Cited by 62
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Michael Lauseker, Alexander Kiani et al.|Leukemia|2024Cited by 25